@article{fdi:010091862,
  title = {{P}harmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy},
  author = {{C}ressey, {T}. and {J}ourdain, {G}onzague and {R}awangban, {B}. and {V}aradisai, {S}. and {K}ongpanichkul, {R}. and {S}absanong, {P}. and {Y}uthavisuthi, {P}. and {C}hirayus, {S}. and {N}go-{G}iang-{H}uong, {N}icole and {V}oramongkol, {N}. and {P}attarakulwanich, {S}. and {L}allemant, {M}arc},
  editor = {},
  language = {{ENG}},
  abstract = {{O}bjective: {T}o evaluate the pharmacokinetics and {HIV} viral load response following initiation during the third trimester of pregnancy of zidovudine plus standard-dose lopinavir boosted with ritonavir ({LPV}/r), twice daily, until delivery for the prevention of mother-to-child transmission of {HIV}. {D}esign: {P}rospective study nested within a multicenter, three-arm, randomized, phase {III} prevention of mother-to-child transmission of {HIV} trial in {T}hailand ({PHPT}-5, {C}linical{T}rials.gov {I}dentifier: {NCT}00409591). {M}ethods: {W}omen randomized to receive 300mg zidovudine and 400/100mg {LPV}/r twice daily from 28 weeks' gestation, or as soon as possible thereafter, until delivery had intensive steady-state 12-h blood sampling performed. {LPV}/r pharmacokinetic parameters were calculated using noncompartmental analysis. {R}ules were defined a priori for a {LPV}/r dose escalation based on the proportion of women with an {LPV} area under the concentration-time curve ({AUC}) below 52 mu g h/ml (10th percentile for {LPV} {AUC} in nonpregnant adults). {HIV}-1 {RNA} response was assessed during the third trimester. {R}esults: {T}hirty-eight women were evaluable; at entry, median (range) gestational age was 29 (28-36) weeks, weight 59.5 (45.0-91.6) kg, {CD}4 cells count 442 (260-1327) cells/mu l and {HIV}-1 {RNA} viral load 7818 (<40-402 015) copies/ml. {G}eometric mean (90% confidence interval) {LPV} {AUC}, {C}-max and {C}-min were 64.6 (59.7-69.8) mu g h/ml, 8.1 (7.5-8.7) mu g/ml and 2.7 (2.4-3.0) mu g/ml, respectively. {T}hirty-one of 38 (81%) women had an {LPV} {AUC} above the {AUC} target. {A}ll women had a {HIV}-1 viral load less than 400 copies/ml at the time of delivery. {C}onclusion: {A} short course of zidovudine plus standard-dose {LPV}/r initiated during the third trimester of pregnancy achieved adequate {LPV} exposure and virologic response.},
  keywords = {lopinavir ; pharmacokinetics ; pregnancy ; prevention of mother-to-child ; transmission of {HIV} ; viral load},
  booktitle = {},
  journal = {{A}ids},
  volume = {24},
  numero = {14},
  pages = {2193--2200},
  ISSN = {0269-9370},
  year = {2010},
  DOI = {10.1097/{QAD}.0b013e32833ce57d},
  URL = {https://www.documentation.ird.fr/hor/fdi:010091862},
}